Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06426407 · ClinicalTrials.gov registry record
Vasopressin Hemodynamic Response as a Septic Shock Subphenotype Indicator
A clinical trial, sponsored by The Cleveland Clinic.
- Terminated
- Registry status
- 2
- Enrollment target
NCT06426407: Clinical Trial study, sponsored by The Cleveland Clinic.
NCT06426407 is a clinical trial that was terminated before completion, run by The Cleveland Clinic. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06426407 was terminated before completion, sponsored by The Cleveland Clinic.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
The goal of this observational study is to learn about blood pressure response to the vasopressor drug vasopressin in people with septic shock. The main questions it aims to answer are: * Are the levels of molecules showing communication between cells different between people whose blood pressure improves and people whose blood pressure does not improve when given a vasopressor medication? * Are measurements found on echocardiography (heart ultrasound) different between people whose blood pressure improves and people whose blood pressure does not improve when given a vasopressor medication? * Are measurements of blood oxygen in tissues just below the skin different between people whose blood pressure improves and people whose blood pressure does not improve when given a vasopressor medication? Participants will be asked to contribute one or two blood samples. Participants who are ordered the drug vasopressin will contribute two blood samples. Both samples will be about two tablespoons for a total of about four tablespoons. One sample will be drawn before starting vasopressin infusion and the second sample will be drawn between one and six hours after starting the vasopressor drug infusion. At the same time points, advanced echocardiography pictures and measurements of oxygen in tissues from a sensor placed on one of the hands will be taken. Participants who are not ordered the drug vasopressin and only ordered the drug norepinephrine will contribute only one blood sample. At the time the sample is collected, advanced echocardiography pictures and measurements of oxygen in tissues from a sensor placed on one of the hands will be taken. This research also involves analyzing data obtained during the participant's hospital stay.
Primary Outcome
Compare baseline ratio of plasma concentrations of interleukin-10 (IL-10) to tumor necrosis factor-α (TNF-α) in vasopressin responders vs. non-responders. The active control cohort of patients who are only receiving norepinephrine will serve as a control for this analysis.
Interventions
- DRUG Vasopressin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2025-10-01 |
| Est. Completion | 2026-02-01 |
Why NCT06426407 stopped before completion
NCT06426407 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Vasopressin is the first listed.
NCT06426407 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06426407 about?
NCT06426407 is a clinical study titled "Vasopressin Hemodynamic Response as a Septic Shock Subphenotype Indicator". The goal of this observational study is to learn about blood pressure response to the vasopressor drug vasopressin in people with septic shock. The main questions it aims to answer are: * Are the levels of molecules showing communication between cells different between people whose blood pressure ...
What is the current status of trial NCT06426407?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2025-10-01. Estimated completion is 2026-02-01.
What interventions are being tested in trial NCT06426407?
The interventions under investigation include: Vasopressin (DRUG).
Who is sponsoring clinical trial NCT06426407?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI